Clinical Trials Browser

Colorectal Neoplasms

NCT06562543 2026-02-27

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

Phase 4 Recruiting

78 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT07136077 2026-02-27

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Phase 2 Recruiting

20 enrolled

Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

NCT07392346 2026-02-11

Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer

Phase 2 Recruiting

68 enrolled

Gastrointestinal

Gastric Cancer Adenocarcinoma Metastatic

NCT07235293 2026-02-03

A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

Phase 2 Recruiting

90 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05867420 2026-01-27

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

Phase 1/2 Recruiting

594 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT05954429 2026-01-22

A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study

Phase 2 Recruiting

50 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT07042685 2026-01-16

Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer

Phase 2 Recruiting

50 enrolled

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT07130903 2025-11-10

Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer

Phase 2 Recruiting

102 enrolled

Gastrointestinal

Metastatic Colorectal Adenocarcinoma

NCT06441565 2025-07-30

Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer

Phase 2/3 Recruiting

84 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06329973 2025-07-17

Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer

Phase 1/2 Recruiting

70 enrolled

Gastrointestinal

Metastatic Gastroesophageal Junction Adenocarcinoma

NCT06356584 2025-06-26

Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

Phase 2 Recruiting

62 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT07003022 2025-06-04

Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC

Phase 2 Recruiting

40 enrolled

Gastrointestinal

Colonic Neoplasms

NCT06980532 2025-05-20

Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer

Phase 1/2 Recruiting

42 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05941325 2025-05-18

A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma

Phase 2 Recruiting

20 enrolled

Sarcoma

NCT05848739 2025-05-11

A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

Phase 1 Recruiting

130 enrolled

Gastrointestinal

Colonic Neoplasms

NCT06791083 2025-01-24

Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer

Phase 2 Recruiting

40 enrolled

Gastrointestinal

Stomach Neoplasms

NCT06427005 2025-01-22

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

Phase 2 Recruiting

66 enrolled

Fruquintinib

NCT06774222 2025-01-14

A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG

Phase 2 Recruiting

69 enrolled

Gastrointestinal

Gastric/Gastroesophageal Junction Adenocarcinoma

NCT06584032 2025-01-07

Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

Phase 3 Recruiting

412 enrolled

Gynecologic

Endometrial Neoplasms

NCT06446154 2024-12-31

Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma

Phase 2 Recruiting

36 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT06685276 2024-11-20

Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer

Phase 2 Recruiting

46 enrolled

Gastrointestinal

Colorectal Cancer Metastatic

NCT06646588 2024-10-17

SJZ-RMEEC01

Phase 2 Recruiting

67 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT06551207 2024-08-13

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

Phase NA Recruiting

80 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06543836 2024-08-09

ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer

Phase 2 Recruiting

68 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06148402 2024-05-13

Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer

Phase 2 Recruiting

30 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06317298 2024-03-19

Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy

Phase NA Recruiting

36 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT06234007 2024-03-18

Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study

Phase 2 Recruiting

45 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06168786 2023-12-21

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

Phase 2 Recruiting

40 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06091423 2023-11-30

XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study

Phase 2 Recruiting

43 enrolled

Gastrointestinal

Stomach Neoplasms

NCT06118762 2023-11-07

Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer

Phase 4 Recruiting

30 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06018714 2023-08-31

Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study

Phase 2 Recruiting

64 enrolled

Gastrointestinal

Colorectal Neoplasms

Clinical Trials

FRUITION

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer

A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study

Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer

Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer

Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer

Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer

Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC

Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer

A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma

A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG

Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma

Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer

SJZ-RMEEC01

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer

Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer

Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy

Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study

Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer

Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study